Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. - Wikidata - awgldk - TriplyDB

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

http://www.wikidata.org/entity/Q34766176

about

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Sulphonylurea monotherapy for patients with type 2 diabetes mellitus Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Characterization of coronary atherosclerosis by intravascular imaging modalities.Stabilization of high-risk plaques Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies Cardiovascular safety of anti-diabetic drugs Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials Hypoglycemic agents and potential anti-inflammatory activity Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications Apoptotic cell clearance: basic biology and therapeutic potential.Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach Imaging plaques to predict and better manage patients with acute coronary events Role of lipotoxicity in endothelial dysfunction Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty Endothelial PPAR-γ Protects Against Vascular Thrombosis by Downregulating P-Selectin ExpressionSignificance β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone Does insulin resistance drive the association between hyperglycemia and cardiovascular risk?Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.The current role of thiazolidinediones in diabetes management.Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.Treatment of hypertension in obese patients.Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure.Progression of coronary atherosclerosis in African-American patients Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond.IVUS-based imaging modalities for tissue characterization: similarities and differences.Systemic correlates of angiographic coronary artery disease.Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.

P2860

Q22241134-C1BC99B6-6C69-4DFE-8FF1-2F6EE833D2CD Q24186660-E415034B-423F-4E2C-9C28-4708B29FCCCB Q24197884-110D6A4E-D4B7-4200-AC9B-73DF11B99ED0 Q24561401-32D2932F-6106-4714-AD39-78863D6E8C58 Q24632655-6985612B-CBDF-45B8-B3F6-824690253898 Q24655666-9403BAD0-8A83-4CB5-8CBC-4D0B9A23B596 Q24658031-B15B6832-C53C-49C7-8FD9-08ABB35D8139 Q26738572-E135893A-311B-42D7-AD20-8A9210F3BBFA Q26738584-37735487-C483-4A24-9663-22E4C2B9AB66 Q26738588-6079EA0E-C444-4116-A6E5-08467C011F4F Q26741082-35B14964-5DBA-4DDE-B105-8034F08D75A7 Q26741860-332E09AF-E02D-43B8-98CD-B10B4669C6D7 Q26748870-9451787B-C9A1-4567-B66C-D8F5B3F869B9 Q26750414-2E613C03-870A-4EF4-AAAE-B011A123F365 Q26824616-20034E7E-1BA5-441E-B847-5A488A9FBF62 Q26825935-F80CEC96-7435-4DF0-A2EB-6CD08B530073 Q26829098-B8E3ADE5-DD2A-4952-A786-DCC8BD1CFAC9 Q26851797-01ED7E21-5368-47DB-8F86-0DE6BB824703 Q26999943-6ED6B1EC-53C8-455C-9157-85FB145BD475 Q27000731-65DDD0CA-1485-4160-BA6A-B28465EC318D Q27022369-B4156976-9398-4E10-B13B-32202CBE967A Q27024799-9D5EEC45-F752-4176-9DBD-955CCA9CA026 Q27342480-57F94791-922B-49A1-A6E4-D4AD38823298 Q27692665-2763490E-D311-431F-9D26-A27FAF3C840E Q28485173-89D3BD52-B951-4530-9A18-C712A8984921 Q28512042-991329A7-F42B-4FD1-8308-44D87C578C60 Q28728387-9A1360AB-DFBE-4D91-AC85-3080BC422988 Q30249371-7B65283E-AD68-4161-A56D-1FE105C31FC8 Q30250347-5134B1F4-D564-4090-B7E5-359BD7BB1FD6 Q30364133-A4870269-C8DA-4CEC-AF25-7A3450B822C6 Q30429298-7EE4945F-ED60-4FB9-B866-3A8E8E701CEA Q30438373-62CB379E-EC2E-4A61-95E7-C2DEB463A432 Q30446789-C119001B-69B3-4533-8FC6-D91E8F5D1E57 Q30475407-8BF959ED-7DE7-47A3-A5C9-CE74BC51AA6B Q30475409-9A0E4D14-FF70-487B-9D91-0BA7FFF788C2 Q33404072-00101983-0AF5-447A-B1E0-B9CC50AE40A3 Q33537687-0757B2CC-26CB-47B7-B7F5-367DE0D51A88 Q33558402-2A8DF803-8082-47F5-90A3-9D5B3CE7DFE1 Q33561396-4C83A5A3-6F57-490A-A9C6-5A8747C63339 Q33585657-A1D5E8EC-F215-4D28-B5BC-4D5506000449

P2860

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

http://www.wikidata.org/entity/Q34766176

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Comparison of pioglitazone vs ...... E randomized controlled trial.

@ast

Comparison of pioglitazone vs ...... E randomized controlled trial.

@en

Comparison of pioglitazone vs ...... E randomized controlled trial.

@nl

type

label

Comparison of pioglitazone vs ...... E randomized controlled trial.

@ast

Comparison of pioglitazone vs ...... E randomized controlled trial.

@en

Comparison of pioglitazone vs ...... E randomized controlled trial.

@nl

prefLabel

Comparison of pioglitazone vs ...... E randomized controlled trial.

@ast

Comparison of pioglitazone vs ...... E randomized controlled trial.

@en

Comparison of pioglitazone vs ...... E randomized controlled trial.

@nl

P1433

Q34766176-CF22EFEC-AF79-4FCF-9D10-F4BB03FD398B

P1476

Q34766176-28ABD2FA-EBA2-4632-9CE0-9F561A48AE7E

P2093

Q34766176-1507F184-AC77-48E8-968D-17B1CA36EAAC

Q34766176-1A1995F5-8E17-46F2-B165-BDCC583CEEF4

Q34766176-20C893AF-B7FE-44EB-BC79-EB6461317AB9

Q34766176-21F206B3-4E5E-4864-98DC-8D74C56F37B0

Q34766176-334EBFF8-1595-4347-ACCB-CBBBB073DC6E

Q34766176-48B5C8AF-3CD8-4ED4-83AD-AEB93C5F32BB

Q34766176-6DC66D12-446A-4F00-9BE8-2BD46BA570D0

Q34766176-6F50860A-631D-4FF7-822F-DCDE98481801

Q34766176-8827FA47-D250-43BC-A7CD-2271E87D65B8

Q34766176-8C086A1B-ED9B-47CD-8249-1907B6633BE9

P304

Q34766176-C0CDB489-0176-44A4-8236-52FF46330140

P31

Q34766176-E882E3CE-E29F-4930-AD08-74F9751F3819

P356

Q34766176-4799AA35-E3C2-47E4-B989-7A953C4208D7

P407

Q34766176-F4CFB5A0-01F0-47BF-96A0-158A640840BC

P433

Q34766176-EE463865-F7FD-4264-80F1-FE3D6E3729BE

P478

Q34766176-E04505AA-4AB0-4395-830A-E2828F31EED6

P50

Q34766176-5A890F26-3EEE-4266-815B-ACB6E28DC686

P577

Q34766176-B48CF24A-629E-4135-BA77-E2387B40DC59

P5875

Q34766176-E9B840FA-7228-41D0-A3BE-E413B77C347E

P698

Q34766176-9B9545BC-D1D4-40D5-B3CB-B72727EB4B5D

P921

Q34766176-51F0D870-89DD-4C91-BAAB-3D404C2BB2D6

Q34766176-C67DB183-D67F-439F-AFC5-2D44056A800E

Q34766176-EB96B53F-4361-4040-AE3B-EA8CDDEB1E4D

P356

JAMA.299.13.1561

P1433

Journal of the American Medical Association

P1476

Comparison of pioglitazone vs ...... E randomized controlled trial.

@en

P2093

Alfonso Perez

http://www.w3.org/2001/XMLSchema#string

Bo Hu

http://www.w3.org/2001/XMLSchema#string

Cezar S Staniloae

http://www.w3.org/2001/XMLSchema#string

E Murat Tuzcu

http://www.w3.org/2001/XMLSchema#string

Horacio Jure

http://www.w3.org/2001/XMLSchema#string

Jacqueline Saw

http://www.w3.org/2001/XMLSchema#string

Kathy Wolski

http://www.w3.org/2001/XMLSchema#string

Kreton Mavromatis

http://www.w3.org/2001/XMLSchema#string

PERISCOPE Investigators

http://www.w3.org/2001/XMLSchema#string

Richard Nesto

http://www.w3.org/2001/XMLSchema#string

P304

1561-1573

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.299.13.1561

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P50

A Michael Lincoff

P577

2008-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5473302

http://www.w3.org/2001/XMLSchema#string

P698

18378631

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

type-2 diabetes